SimulationsPlus (SLP) Q4 2025 earnings review
Growth Reverses Sharply, FY26 Guidance Signals Prolonged Slowdown
Simulations Plus reported a challenging fourth quarter, with revenue declining 6% YoY to $17.5 million, a sharp reversal from the double-digit growth seen earlier in the year. The downturn was broad-based, with both the Software (-9%) and Services (-3%) segments contracting. While the company met its revised (and lowered) full-year guidance, the anemic outlook for fiscal 2026—projecting just 0-4% revenue growth and a negative start in Q1—suggests the difficult macro environment for its biopharma clients is expected to persist. The underperformance of the recently acquired Pro-ficiency asset, highlighted by a 63% Q4 revenue collapse in its software platform, remains a significant concern.
🐂 Bull Case
Management is aggressively pivoting to an integrated product vision centered on AI and cloud capabilities, starting with the GastroPlus X.2 release. If successful, this could create a significant competitive advantage and re-accelerate growth in the long term.
Despite a decline in Q4 Services revenue, the ending backlog grew 28% YoY to $18.0 million. This provides some visibility for revenue conversion in FY26, assuming project delays which plagued prior quarters do not worsen.
🐻 Bear Case
After a year of growth, the business slammed into reverse in Q4. The reversal from +10% revenue growth in Q3 to -6% in Q4 indicates a rapid deterioration in the operating environment that management's narrative on 'resilience' fails to capture.
The forecast of 0-4% revenue growth for FY26, with Q1 expected to decline 3-5% YoY, points to a prolonged period of stagnation and suggests management has little confidence in a near-term market recovery.
The Pro-ficiency software platform, a key part of a recent major acquisition, saw revenue collapse 63% YoY in Q4. This follows a $77.2 million impairment charge on the asset in Q3, confirming significant issues with the acquisition's performance and strategy.
⚖️ Verdict: 🔴🔴
Very Bearish. The sharp reversal into negative growth across both core segments, coupled with a dismal FY26 outlook and deteriorating software renewal rates, paints a bleak near-term picture. The severe underperformance of the key Pro-ficiency acquisition is a major red flag regarding capital allocation and execution. The positive narrative around a future AI pivot is insufficient to offset the current, negative data trends.
Key Themes
Pro-ficiency Acquisition Fails to Perform
A critical red flag is the severe underperformance of the Pro-ficiency acquisition. Its software platform revenue collapsed 63% YoY in Q4. This poor result follows the company taking a massive $77.2 million non-cash impairment charge in Q3, primarily related to Pro-ficiency, to write down its value. The asset acquired to diversify revenue and double the TAM is now a significant drag on growth, raising serious questions about the deal's rationale and integration.
Deteriorating Software Renewal Rates
A core pillar of the investment case—the stickiness of its software—is showing cracks. The fee-based renewal rate fell to 83% in Q4, pulling the full-year FY25 rate down to 88%. This is a notable decline from 93% in FY24 and 92% in FY23. Management attributes the drop to client consolidations, but a sustained trend below the historical 90%+ range could indicate increased competitive pressure or clients trimming non-essential software modules to cut costs.
Pivot to AI and Cloud-Native Platform
Management is staking the company's future on a strategic pivot to an integrated, AI-driven, cloud-based ecosystem. The initial rollout includes the GastroPlus X.2 release and S+ Cloud platform. The stated goal is to connect all flagship products (GastroPlus, MonolixSuite, ADMET Predictor) to deliver AI-assisted workflows, faster cycle times, and better interoperability. While still in early stages, this strategy correctly aligns with industry trends and could become a significant long-term growth driver and competitive moat if successfully executed.
Biopharma Macro Headwinds Persist
Management continues to attribute weak performance to a challenging macro environment for its biopharma clients, citing cautious spending, budget constraints, and uncertainty around funding and drug pricing. The FY26 guidance, which assumes these conditions remain stable, confirms that the company does not see a market recovery on the immediate horizon.
Margin Compression in Q4
Profitability took a significant hit in the fourth quarter. Adjusted EBITDA margin compressed to 20%, a steep drop from 37% in Q3 and 22% in the prior year. This demonstrates negative operating leverage, as the sharp revenue decline was not matched by cost reductions, highlighting the vulnerability of the P&L to top-line volatility.
Other KPIs
The company reported a substantial GAAP net loss for the full year, a stark contrast to the $10.0 million profit in FY24. The loss was driven entirely by the $77.2 million non-cash goodwill impairment charge related to the underperforming Pro-ficiency acquisition, which wiped out all operating profits for the year.
Decelerating. After peaking at 37% in Q3, the adjusted EBITDA margin collapsed to 20% in Q4. This demonstrates the company's limited ability to flex its cost structure in the face of a rapid revenue decline, resulting in significant deleveraging. The full-year margin of 28% was down slightly from 29% in FY24.
Guidance
Decelerating. The midpoint of $80.5M implies just 1.6% YoY growth, a dramatic slowdown from the 13% growth achieved in FY25. This guidance signals that management expects the current market headwinds and internal challenges to persist for the entire upcoming fiscal year.
Decelerating. The midpoint of $1.065 implies 3.4% YoY growth, a slowdown from 8% growth in FY25. This suggests minimal operating leverage and continued pressure on profitability in the coming year.
Reversing/Negative. Management explicitly guided for a negative start to the fiscal year, with Q1 revenue expected to decline year-over-year. This sets a weak baseline and requires a significant re-acceleration in the back half of the year just to meet the low single-digit full-year growth target.
Key Questions
Pro-ficiency Software Collapse
The Pro-ficiency software platform revenue declined 63% in Q4. Can you provide a more detailed breakdown of what caused this collapse, whether it's related to customer losses, project completions, or pricing, and how this performance impacts your long-term strategy for the clinical ops market?
Path to Growth in FY26
Given the guidance for a negative Q1 and only 0-4% growth for the full year, what specific catalysts or pipeline developments give you confidence in a re-acceleration in the second half of FY26? Are you banking on a market recovery or specific product launches?
Renewal Rate Sustainability
The fee-based renewal rate has now fallen to 83%. While you've cited client M&A, is there any evidence of increased 'module shaving' by clients to cut costs or heightened competitive pressure? What is your internal forecast for this crucial metric in FY26?